Atyr Pharma在即将到来的Keystone专题讨论会上介绍了对ATYR0101新纤维化治疗的研究。 ATyr Pharma presents research on new fibrosis treatment ATYR0101 at upcoming Keystone Symposia.

Atyr Pharma是一家生物技术公司,它将于2024年12月8日至11日在加拿大的Fibrosis Keystone专题讨论会上展示其候选人ATYR0101的两张海报。 ATyr Pharma, a biotech company, will present two posters on its candidate ATYR0101 at the Keystone Symposia on Fibrosis from December 8-11, 2024, in Canada. 海报将讨论该药物在肺和肾模型中的抗纤维化作用及其与蛋白质的相互作用,这些蛋白质可能有助于治疗纤维化和炎症。 The posters will discuss the drug's anti-fibrotic effects in lung and kidney models and its interaction with proteins that may help treat fibrosis and inflammation. ATYR0101是Atyr基于tRNA合成酶生物学开发新疗法努力的一部分。 ATYR0101 is part of ATyr's efforts to develop new therapies based on tRNA synthetase biology.